Pee Dee Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.86 M
- Company Age 33 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.57 M
- Revenue Growth 3.95%
- Profit Growth -63.77%
- Ebitda 47.19%
- Net Worth 0.33%
- Total Assets -10.25%
About Pee Dee Pharma
Pee Dee Pharma Pvt Ltd (PDPPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 June 1991 and has a history of 33 years and seven months. Its registered office is in Kolkata, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.86 M.
The company currently has active open charges totaling ₹5.57 M.
Debi Datta and Prasanta Datta serve as directors at the Company.
Company Details
-
Location
Kolkata, West Bengal, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232WB1991PTC052082
-
Company No.
052082
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Jun 1991
-
Date of AGM
25 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Pee Dee Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Debi Datta
|
Director | 20-Jun-1991 | Current |
|
Prasanta Datta
|
Director | 20-Jun-1991 | Current |
Financial Performance of Pee Dee Pharma.
Pee Dee Pharma Pvt Ltd, for the financial year ended 2023, experienced modest growth in revenue, with a 3.95% increase. The company also saw a substantial fall in profitability, with a 63.77% decrease in profit. The company's net worth moved up by a moderate rise of 0.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pee Dee Pharma?
In 2023, Pee Dee Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Stafford Laboratories Private LimitedDebi Datta and Prasanta Datta are mutual person
-
Stafford Health Care LlpDebi Datta is a mutual person
Charges (Loans)
₹5.57 M
₹0
Charges Breakdown by Lending Institutions
- Union Bank Of India : 0.49 Cr
- Others : 0.07 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Jun 2020 | Others | ₹0.67 M | Open |
| 14 Dec 2004 | Union Bank Of India | ₹3.40 M | Open |
| 12 Jul 1999 | Union Bank Of India | ₹1.50 M | Open |
How Many Employees Work at Pee Dee Pharma?
Unlock and access historical data on people associated with Pee Dee Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pee Dee Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pee Dee Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
